flurbiprofen
RxCUI 4502
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Flurbiprofen
Flurbiprofen is a member of the phenylalkanoic acid derivative family of nonsteroidal anti-inflammatory drugs (NSAIDs). It is primarily indicated as a pre-operative anti-miotic (in an ophthalmic solution) as well as orally for arthritis or dental pain. Side effects are analogous to those of ibuprofen. It was derived from propionic acid by the research arm of Boots UK during the 1960s, a period which also included the discovery of ibuprofen, indometacin, diclofenac, naproxen, ketoprofen, and sulindac. It was patented in 1964 by Boots UK and approved for medical use in 1987. It was approved in the US in 1988; the first generic was approved in 1994.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
2 shownConditions being studied
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.